Mesothelioma is staged from 1 through 4, with each stage reflecting how far the cancer has spread from its original location in the lining of the lungs, abdomen, or heart. The formal staging system applies to pleural mesothelioma (the most common type, affecting the lung lining) and uses four numbered stages based on tumor size, lymph node involvement, and whether the cancer has reached distant parts of the body. Five-year survival rates for pleural mesothelioma range from about 7% to 24% depending on the stage at diagnosis, and average survival with treatment is roughly 18 months.
How Mesothelioma Staging Works
Doctors stage pleural mesothelioma using the TNM system, which evaluates three things: how large and invasive the primary tumor is (T), whether cancer has reached nearby lymph nodes (N), and whether it has metastasized to distant organs (M). The current system is based on the 8th edition of the AJCC staging manual, though a 9th edition is in development. That upcoming revision introduces a notable change: standardized measurements of pleural thickness on CT scans at three specific points, which researchers have found to be a reliable predictor of survival.
For treatment planning, oncologists often simplify staging into two practical categories: resectable (tumors that surgery can fully remove) and unresectable (tumors that have spread too far for complete surgical removal). Most stage I and II mesotheliomas are resectable, along with some stage III cases. Stage IV is generally unresectable.
Stage 1: Localized Tumor
In stage 1, the tumor is confined to the pleura (the thin membrane surrounding one lung). It has not spread to lymph nodes or distant sites. At this point, the cancer may affect only one layer of the pleura or may have started growing into both the inner and outer layers on the same side of the chest.
Symptoms at this stage are often mild and easy to mistake for a respiratory condition like asthma or a lingering chest cold. You might notice shortness of breath, a persistent cough, chest pressure, or low-grade fever. Because these symptoms overlap with so many common illnesses, stage 1 mesothelioma is rarely caught without deliberate screening or incidental imaging findings.
Stage 1 offers the widest range of treatment options. Surgery to remove visible tumor is typically feasible, often combined with chemotherapy or radiation.
Stage 2: Early Spread to Nearby Tissue
Stage 2 mesothelioma has grown deeper into surrounding structures on the same side of the chest. The tumor may have invaded the lung tissue itself, the diaphragm, or the fatty tissue between the lungs. Lymph nodes on the same side of the body may or may not be involved.
Symptoms become more noticeable. Fluid often begins building up between the lung and chest wall (a pleural effusion), creating a feeling of tightness or pressure. Weight loss may start, and the breathing difficulties and chest pain from stage 1 typically worsen. The cancer is still generally considered resectable at this point, though the decision depends on the tumor’s exact location, its cell type, and the patient’s overall health.
Stage 3: Regional Spread
At stage 3, the cancer has spread more extensively within the chest. This can mean the tumor has grown into the chest wall, the tissue surrounding the heart, or nearby structures, and cancer cells have typically reached lymph nodes on the same side of the chest. Some stage 3 cases involve lymph nodes on the opposite side or above the collarbone.
By this point, symptoms interfere with daily life. Chest pain and pressure intensify, and breathing becomes increasingly difficult. Many patients experience significant fatigue and continued weight loss. Some stage 3 mesotheliomas are still surgically resectable, but this depends heavily on which specific structures are involved and how extensive the lymph node spread is. Treatment more commonly relies on chemotherapy, immunotherapy, or radiation to control the disease and manage symptoms.
Stage 4: Distant Metastasis
Stage 4 mesothelioma has spread to distant organs or to the pleura on the opposite side of the chest. The tumor may have also grown into structures that make local removal impossible: bones of the chest wall (such as ribs), the heart, spine, esophagus, trachea, major blood vessels, or through the diaphragm into the abdomen. Fluid may accumulate around the heart (pericardial effusion).
Symptoms at stage 4 extend beyond the chest. In addition to severe breathing difficulty and chest pain, patients often experience significant weight loss, drenching night sweats, deep fatigue, and a complete loss of appetite. The cancer is considered unresectable at this stage. Treatment focuses on slowing progression and relieving symptoms through chemotherapy, immunotherapy, radiation, or procedures to drain fluid buildup. Research from the international staging committee has confirmed that the mere presence of metastatic disease matters more for outcomes than the specific number or location of distant sites.
How Cell Type Affects Outlook
Stage alone doesn’t determine prognosis. The cell type of the tumor plays a major role. Mesothelioma comes in three subtypes:
- Epithelioid: The most common subtype and the one with the best prognosis. These tumors tend to grow more slowly and respond better to treatment.
- Sarcomatoid: The least favorable subtype. Sarcomatoid mesothelioma spreads more quickly and is harder to treat.
- Biphasic (mixed): Contains both epithelioid and sarcomatoid cells. Tumors with a higher proportion of epithelioid cells carry a better outlook than those dominated by sarcomatoid cells.
Two patients with the same stage can have very different experiences depending on which cell type their biopsy reveals. Subtype also influences whether surgery is recommended, since sarcomatoid tumors are more likely to recur after resection.
How Doctors Determine Your Stage
Staging relies on a combination of imaging and, in many cases, surgical biopsy. CT scans are the foundation, providing detailed views of tumor size and spread. PET-CT scans add a layer of information by highlighting metabolically active cancer cells, which helps detect hidden metastases in lymph nodes or distant organs that a standard CT might miss. PET-CT is also useful for distinguishing active tumor from scar tissue after treatment.
MRI is typically reserved for specific questions about whether the tumor has invaded the diaphragm, chest wall, or structures in the center of the chest. It provides better soft-tissue contrast than CT in these areas. Together, these tools help the oncology team map the cancer’s extent and determine whether surgery is a realistic option.
Peritoneal Mesothelioma Staging
Peritoneal mesothelioma, which develops in the lining of the abdomen, does not use the same four-stage TNM system. Instead, doctors typically assess it using the Peritoneal Cancer Index (PCI), a scoring system that divides the abdomen into 13 regions and assigns a score based on tumor size in each one. The total score helps determine whether cytoreductive surgery (removing all visible tumor from the abdominal cavity) is feasible. Because peritoneal mesothelioma accounts for a smaller share of cases and behaves differently than the pleural form, it follows its own treatment and staging pathway.